FitzGerald JM, et al. - This study entailed a further exploration of the efficacy of benralizumab for severe asthmatics with different baseline blood eosinophil thresholds and exacerbation histories. In patients in the 4-weekly and 8-weekly benralizumab groups, it was observed that the extent to which exacerbation rates were reduced increased with increasing blood eosinophil thresholds and with greater exacerbation history. In addition, it was noted that in patients with a combination of high blood eosinophil thresholds and a history of more frequent exacerbations, benralizumab vs placebo led to greater improvements in annual exacerbation rate. For decision making regarding the use of benralizumab to treat patients with severe, uncontrolled, eosinophilic asthma, these data will help to guide clinicians.